推荐应用
Functional IL-2 receptors can exist in two affinity states on cell surfaces, the high affinity complex consisting of heterotrimers of the alpha, beta, and gamma chains, and the intermediate affinity complex comprising heterodimers of the beta and gamma chains. Individual beta chains and alpha chains exhibit low affinity IL-2 binding and the gamma chain alone does not bind IL-2. In addition to their involvement in IL-2 mediated signal transduction, both the beta chain and gamma chain have been shown to be required for IL-15 mediated signaling. IL-2 R beta is a member of the cytokine receptor superfamily. Human IL-2 R beta cDNA encodes a 551 amino acid residue precursor Type I membrane protein with a 26 residue signal peptide, a 214 residue extracellular region, a 25 residue transmembrane region and a 286 residue cytoplasmic domain. A soluble IL-2 R beta (IL-2 sR beta ) has been identified in the culture supernatants of a human lymphoid cell line, YT, that displays IL-2 R beta. At present, the function of IL-2 sR beta is unclear. Recombinant human IL-2 sR beta binds IL-2 with low affinity and is not an effective IL-2 antagonist on cells displaying the high or intermediate affinity IL-2 signaling receptors. Nevertheless, IL-2 sR beta binds IL-15 with sufficient affinity to neutralize IL-15 biological activities.
高纯度、高活性、低内毒素、高批间一致性
产品数据
Tris-Bis PAGE


-25 ~ -15℃保存,收到货之后有效期1年。 复溶后, 无菌条件下,-85 ~ -65℃保存,3个月有效期。
【应用方向】GPC3:HCC靶向治疗的核心靶点与药物研发探索
779
2026-04-24
【应用方向】TROP2:从分子机制到实体瘤靶向治疗的研究进展
812
2026-04-24
【应用方向】4-1BB-4-1BBL共刺激轴的T细胞活化机制
498
2026-04-22
【应用方向】TNFR蛋白家族概述
514
2026-04-21
【应用方向】Klotho蛋白:编织生命之线的抗衰老分子
545
2026-04-20
【应用方向】药靶明星 | FGFRs家族蛋白解析
459
2026-04-20
【应用方向】解析Fc受体:抗体药物研发的核心靶点与评价基石
458
2026-04-20
【应用方向】FcγR家族:抗体药物研发的基石与核心靶点
451
2026-04-20
【应用方向】CD47-SIRPα轴研究工具与药物开发应用
435
2026-04-20
【技术讲解】ADC药物研究相关靶点汇总
18926
2025-07-30
【应用方向】抗体药筛选的关键—靶点蛋白
10852
2025-07-09
【技术讲解】重要免疫检查点:PD-1及其配体
20197
2025-07-24
【应用方向】药靶明星|FGFs&FGFRs家族蛋白解析
18506
2025-07-24
【应用方向】热门肿瘤靶点蛋白-EGFR表皮生长因子受体
6307
2025-07-24
【技术讲解】双抗热门靶点-双特异性抗体靶点CD3D&CD3E
14722
2022-09-05





